BRPI0507545A - composições e métodos para o tratamento e remissão clìnica de psorìase - Google Patents

composições e métodos para o tratamento e remissão clìnica de psorìase

Info

Publication number
BRPI0507545A
BRPI0507545A BRPI0507545-9A BRPI0507545A BRPI0507545A BR PI0507545 A BRPI0507545 A BR PI0507545A BR PI0507545 A BRPI0507545 A BR PI0507545A BR PI0507545 A BRPI0507545 A BR PI0507545A
Authority
BR
Brazil
Prior art keywords
psoriasis
treatment
compositions
methods
clinical remission
Prior art date
Application number
BRPI0507545-9A
Other languages
English (en)
Inventor
Jose Antonio O'daly
Original Assignee
Astralis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astralis Llc filed Critical Astralis Llc
Publication of BRPI0507545A publication Critical patent/BRPI0507545A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSIçÈES E MéTODOS PARA O TRATAMENTO E REMISSãO CLìNICA DE PSORìASE Um tratamento para psoríase e malgnidades relacionadas tem um mecanismo de ação que inclui uma inibição ou bloqueio de rolamento de células T através de interferência na interação CLA/E-selectina e interferência na ligação endotelial ou diapedese induzida através de bloqueio da interação LFA-1/ICAM e/ou da interação VLA/VCAM com células endoteliais.
BRPI0507545-9A 2004-02-09 2005-02-08 composições e métodos para o tratamento e remissão clìnica de psorìase BRPI0507545A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/774,928 US20040241168A1 (en) 2001-03-16 2004-02-09 Compositions and methods for the treatment and clinical remission of psoriasis
PCT/US2005/003994 WO2005084444A1 (en) 2004-02-09 2005-02-08 Compositions and methods for the treatment and clinical remission of psoriasis

Publications (1)

Publication Number Publication Date
BRPI0507545A true BRPI0507545A (pt) 2007-07-03

Family

ID=34919679

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507545-9A BRPI0507545A (pt) 2004-02-09 2005-02-08 composições e métodos para o tratamento e remissão clìnica de psorìase

Country Status (8)

Country Link
US (1) US20040241168A1 (pt)
EP (1) EP1720410A4 (pt)
JP (1) JP2007522221A (pt)
AU (1) AU2005220149A1 (pt)
BR (1) BRPI0507545A (pt)
CA (1) CA2555612A1 (pt)
MX (1) MXPA06009076A (pt)
WO (1) WO2005084444A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241168A1 (en) * 2001-03-16 2004-12-02 O'daly Jose A. Compositions and methods for the treatment and clinical remission of psoriasis
WO2008131301A1 (en) * 2007-04-18 2008-10-30 Massachusetts Institute Of Technology Surfaces, methods and devices employing cell rolling
EP2205725A4 (en) * 2007-09-27 2012-01-04 Massachusetts Inst Technology CELL ROLLER SEPARATION
US20140356391A1 (en) * 2013-05-29 2014-12-04 Jose Antonio O'Daly Amino acid sequences for clinical remission of psoriasis and related diseases.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3581288D1 (de) * 1984-10-01 1991-02-14 Pasteur Institut Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
US4687666A (en) * 1985-02-19 1987-08-18 Ministerio De Sanidad Y Asistencia Social Instituto Venezolano De Investigationes Cientificas Vaccine for Leishmaniasis
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5202320A (en) * 1989-04-06 1993-04-13 Tidwell Richard R Method for treating leishmaniasis
US5674503A (en) * 1990-07-24 1997-10-07 University Of Victoria Peptides capable of eliciting an immune response to leishmaniasis and methods of using the same
FR2682107B1 (fr) * 1991-10-03 1995-04-21 Orstom Inst Fs Rech Scient Quinoleines 2-substituees pour le traitement des leishmanioses.
US5411865A (en) * 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
PT716697E (pt) * 1993-09-03 2003-08-29 Univ Mcgill Genes e proteinas de leishmania expressos diferencialmente
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US5876735A (en) * 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
WO1995029699A1 (en) * 1994-04-29 1995-11-09 Curtis Powell Vaccine for, diagnostic assay for and method of treating parasitic hemoflagellate protozoa
US6174995B1 (en) * 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US5496830A (en) * 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US5912166A (en) * 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US5928928A (en) * 1995-06-07 1999-07-27 Universiteit Van Amsterdam Human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases
US5965142A (en) * 1995-08-04 1999-10-12 Corixa Corporation Polypeptides and methods for the detection of L. tropica infection
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6162638A (en) * 1996-05-06 2000-12-19 Universite Laval Attenuated strains of leishmania and uses thereof
US5952194A (en) * 1996-08-01 1999-09-14 Heska Corporation Flea nucleic acid sequences and uses thereof
AU727781B2 (en) * 1997-04-02 2000-12-21 Bioniche Life Sciences Inc. Use of bacterial cell wall extract for preventing, treating, or eliminating a protozoal or parasitic disease
US5854051A (en) * 1997-09-15 1998-12-29 Heska Corporation Parasitic helminth asparaginase proteins, nucleic acid molecules, and uses thereof
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US6568952B1 (en) * 2000-08-02 2003-05-27 Swenco Products, Inc. T-tap connector
US6673351B1 (en) * 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
US20040241168A1 (en) * 2001-03-16 2004-12-02 O'daly Jose A. Compositions and methods for the treatment and clinical remission of psoriasis

Also Published As

Publication number Publication date
JP2007522221A (ja) 2007-08-09
WO2005084444A1 (en) 2005-09-15
EP1720410A4 (en) 2008-07-02
EP1720410A1 (en) 2006-11-15
US20040241168A1 (en) 2004-12-02
MXPA06009076A (es) 2007-03-08
CA2555612A1 (en) 2005-09-15
AU2005220149A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
BRPI0818437B8 (pt) anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
ATE323501T1 (de) Pharmazeutische zusammensetzung enthaltend proteoglykan und ihre verwendung zur behandlung von entzündlichen erkrankungen
BRPI0721503A8 (pt) composições e métodos para tratamento de um poço bloqueado por água
BR0012595A (pt) Ligação de fonte de dados de célula em folha de desenvolvimento
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
BRPI0516727A (pt) métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença
BRPI0614184A8 (pt) Redução de células b com o uso de moléculas de ligação específicas para cd37 e específicas para cd20
CL2007002682A1 (es) Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
BRPI0618577A8 (pt) Usos de rituximab
BR112012031612A2 (pt) montagem de caixa para dejetos dotada de um dispositivo de fragmentação de granulado sanitário
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
BRPI1007048A2 (pt) método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
AR066527A1 (es) Panel para la contruccion de edificios con salientes perpendiculares a una cara
ATE510242T1 (de) Ablagerungsminderungssystem mit verbesserter gasverteilung
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
BRPI0507545A (pt) composições e métodos para o tratamento e remissão clìnica de psorìase
BRMU8602727U (pt) disposição construtiva introduzida em tampa
BRPI0612424A2 (pt) composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
BRPI0502073A (pt) Conjunto estojo
BRPI0520449B8 (pt) artigo absorvente tendo características de mascaramento de mancha
BRPI0517454A (pt) recipiente compreendendo um fundo, uma parede e uma folha de fechamento orientada a partir do fundo para fechamento do recipiente e método para produção de um recipiente
FR2916044B1 (fr) Systeme global electronique d'economies d'energies et de securites individuelles.
TW200616651A (en) Mussel extract composition with enhanced anti-inflammatory activity
Diem et al. Using a Water Budget Approach to Quantify Inflow and Infiltration Impacts on Urban Streamflow

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]